Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial

INTRODUCTION: The novel coronavirus pandemic (COVID–19) represents a major public health problem and it is key to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortality in subjects with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez-Cardenas, Carmen, Thirion-Romero, Ireri, Rodríguez-Llamazares, Sebastián, Rivera-Martinez, Norma E., Meza-Meneses, Patricia, Remigio-Luna, Arantxa, Perez-Padilla, Rogelio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478184/
https://www.ncbi.nlm.nih.gov/pubmed/34582477
http://dx.doi.org/10.1371/journal.pone.0257238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478184/
https://www.ncbi.nlm.nih.gov/pubmed/34582477
http://dx.doi.org/10.1371/journal.pone.0257238

Ejemplares similares